- Precision BioSciences Inc (NASDAQ:DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)
- PBCAR19B is an immune-evading allogeneic CAR T stealth cell candidate.
- The study’s primary objective is to identify the maximum tolerated dose and any dose-limiting toxicities.
- Price Action: DTIL shares are down 0.16% at $12.50 during the market session on the last check Thursday.
Recap: Pacific Mercantile Q2 Earnings
Shares of Pacific Mercantile (NASDAQ:PMBC) decreased 0.7% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 125.00% year over year to $0.18, which beat the estimate of $0.16.
